InvestorsHub Logo
Followers 55
Posts 13535
Boards Moderated 0
Alias Born 10/12/2006

Re: RockinTop post# 659

Monday, 11/13/2017 8:52:53 PM

Monday, November 13, 2017 8:52:53 PM

Post# of 3504
interesting info in the 10Q that I wasn't aware of previously.

The Annamycin drug substance is no longer covered by any existing patent protection. On July 18, 2017, the Company announced that it had signed a new technology license agreement with MD Anderson Cancer Center based on new patent applications that the Company intends to file relating to Annamycin. These patent applications are related to the formulation, synthetic process and reconstitution related to our Annamycin drug product candidate, although there is no assurance that we will be successful in obtaining such patent protection.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MBRX News